Galmed Pharmaceuticals Ltd
GLMD
View Detailed Chart
1.190USD
-0.145-10.85%
Close 11/04, 16:00（ET）Quotes delayed by 15 min
6.31MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-10.85%
5 Days
-19.03%
1 Month
-24.19%
6 Months
-4.78%
Year to Date
-62.69%
1 Year
-63.27%
View Detailed Chart
TradingKey Stock Score of Galmed Pharmaceuticals Ltd
Currency: USD Updated: 2025-11-04Key Insights
The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a very weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Galmed Pharmaceuticals Ltd's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Hold
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Galmed Pharmaceuticals Ltd Highlights
StrengthsRisks
Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
Overvalued
The company’s latest PE is -0.27, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 77.70K shares, decreasing 13.26% quarter-over-quarter.
Galmed Pharmaceuticals Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Galmed Pharmaceuticals Ltd Info
Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
Ticker SymbolGLMD
CompanyGalmed Pharmaceuticals Ltd
CEOMr. Allen Baharaff
Websitehttps://www.galmedpharma.com
Related Instruments
+1.15%
+0.32%
+1.85%
+0.38%
+0.93%
+1.66%
-1.75%
+0.13%
+0.78%
-1.46%
-1.88%
-1.02%
+2.61%
+1.01%
-0.93%
-0.64%
0.00%
-2.22%
-2.44%
-13.78%Popular Symbols
